RESUMO
BACKGROUND: Previous estimates of the cost of care for pediatric Cystic fibrosis (CF) showed wide variation, without specific summary of pulmonary drug costs. METHODS: Enrolled CF children from the Wisconsin newborn screening trial were evaluated quarterly per protocol. Assessments systematically included all treatments, hospitalizations, and nutritional and pulmonary outcomes. Direct medical costs from hospital billing and medical records from 1989 to 2010 were used to describe costs by age-ranges and subgroups throughout follow-up. Outpatient drugs were separated by category (pulmonary/otherwise). Inpatient and drug costs were examined by clinical risk factors (presence of meconium ileus, pancreatic insufficiency, and expected severity of genetic mutations). RESULTS: Seventy-three children were followed for an average of 12.9 years with an average annual total cost of care of $24,768. Outpatient drug costs (53%) and hospitalizations (32%) represented the majority of costs. Drug costs were 48% for pulmonary indications and 52% for non-pulmonary. Pulmonary drug costs for children taking dornase were 54% of their drug costs while pulmonary drug costs were only 31% for children not taking dornase. Significant differences in frequency of inpatient stays existed for children with pancreatic insufficiency. Substantial differences in treatment costs exist as children age and by clinical risk factor. CONCLUSION: This study provides more accurate longitudinal estimates of CF care costs throughout childhood and shows that increasing age, pancreatic insufficiency, use of dornase, and hospitalizations are key determinants of cost. These estimates can be included in evaluations of the cost-effectiveness of new, highly expensive treatments being introduced for any CF population. Pediatr Pulmonol. 2016;51:1295-1303. © 2016 Wiley Periodicals, Inc.
Assuntos
Assistência Ambulatorial/economia , Fibrose Cística/economia , Desoxirribonuclease I/economia , Custos de Medicamentos , Insuficiência Pancreática Exócrina/economia , Custos de Cuidados de Saúde , Hospitalização/economia , Adolescente , Criança , Pré-Escolar , Análise Custo-Benefício , Fibrose Cística/complicações , Fibrose Cística/tratamento farmacológico , Desoxirribonuclease I/uso terapêutico , Insuficiência Pancreática Exócrina/etiologia , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Estudos Longitudinais , Masculino , Triagem Neonatal , Proteínas Recombinantes/economia , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , WisconsinRESUMO
BACKGROUND: Among late postoperative complications of pancreatectomy are the exocrine and endocrine pancreatic insufficiencies. The presence of exocrine pancreatic insufficiency imposes, as standard treatment, pancreatic enzyme replacement. Patients with chronic pancreatitis, with intractable pain or any complications with surgical treatment, are likely to present exocrine pancreatic insufficiency or have this condition worsened requiring adequate dose of pancreatic enzymes. OBJECTIVE: The aim of this study is to compare the required dose of pancreatic enzyme and the enzyme replacement cost in post pancreatectomy patients with and without chronic pancreatitis. METHODS: Observational cross-sectional study. In the first half of 2015 patients treated at the clinic of the Department of Gastrointestinal Surgery at Hospital das Clínicas, Universidade de São Paulo, Brazil, who underwent pancreatectomy for at least 6 months and in use of enzyme replacement therapy were included in this series. The study was approved by the Research Ethics Committee. The patients were divided into two groups according to the presence or absence of chronic pancreatitis prior to pancreatic surgery. For this study, P<0.05 was considered statistically significant. RESULTS: The annual cost of the treatment was R$ 2150.5 ± 729.39; R$ 2118.18 ± 731.02 in patients without pancreatitis and R$ 2217.74 ± 736.30 in patients with pancreatitis. CONCLUSION: There was no statistically significant difference in the cost of treatment of enzyme replacement post pancreatectomy in patients with or without chronic pancreatitis prior to surgical indication.
Assuntos
Terapia de Reposição de Enzimas/economia , Insuficiência Pancreática Exócrina/tratamento farmacológico , Pancreatectomia/efeitos adversos , Neoplasias Pancreáticas/cirurgia , Pancreatite Crônica/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Insuficiência Pancreática Exócrina/economia , Insuficiência Pancreática Exócrina/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
ABSTRACT Background - Among late postoperative complications of pancreatectomy are the exocrine and endocrine pancreatic insufficiencies. The presence of exocrine pancreatic insufficiency imposes, as standard treatment, pancreatic enzyme replacement. Patients with chronic pancreatitis, with intractable pain or any complications with surgical treatment, are likely to present exocrine pancreatic insufficiency or have this condition worsened requiring adequate dose of pancreatic enzymes. Objective - The aim of this study is to compare the required dose of pancreatic enzyme and the enzyme replacement cost in post pancreatectomy patients with and without chronic pancreatitis. Methods - Observational cross-sectional study. In the first half of 2015 patients treated at the clinic of the Department of Gastrointestinal Surgery at Hospital das Clínicas, Universidade de São Paulo, Brazil, who underwent pancreatectomy for at least 6 months and in use of enzyme replacement therapy were included in this series. The study was approved by the Research Ethics Committee. The patients were divided into two groups according to the presence or absence of chronic pancreatitis prior to pancreatic surgery. For this study, P<0.05 was considered statistically significant. Results - The annual cost of the treatment was R$ 2150.5 ± 729.39; R$ 2118.18 ± 731.02 in patients without pancreatitis and R$ 2217.74 ± 736.30 in patients with pancreatitis. Conclusion - There was no statistically significant difference in the cost of treatment of enzyme replacement post pancreatectomy in patients with or without chronic pancreatitis prior to surgical indication.
RESUMO Contexto - Dentre as complicações pós-operatórias tardias da pancreatectomia estão as insuficiências pancreáticas exócrina e endócrina. O reconhecimento da presença de insuficiência pancreática exócrina impõe, como tratamento padrão, a reposição de enzimas pancreáticas. Pacientes portadores de pancreatite crônica, com dor clinicamente intratável ou com alguma complicação com indicação de tratamento cirúrgico, podem vir a apresentar insuficiência pancreática exócrina ou ter essa condição agravada requerendo adequação de dose de enzimas pancreáticas. Objetivo - O objetivo deste estudo é comparar a dose necessária de enzima pancreática e o custo do tratamento de reposição enzimática em pacientes pancreatectomizados, com e sem pancreatite crônica. Métodos - Estudo transversal observacional. No primeiro semestre de 2015 pacientes acompanhados no ambulatório de Cirurgia do Aparelho Digestivo do HC-FMUSP, submetidos a pancreatectomia há pelo menos 6 meses e em terapia de reposição enzimática foram incluídos nessa casuística. O estudo foi aprovado pelo Comitê de Ética. Os pacientes foram divididos em dois grupos, de acordo com a presença ou ausência de pancreatite crônica prévia à cirurgia pancreática. Para este estudo, P<0,05 foi considerado como estatisticamente significante. Resultados - O custo anual do tratamento foi R$ 2150,51 ± 729,39; R$ 2118,18 ± 731,02 em pacientes sem pancreatite crônica e R$ 2217,74 ± 736,30 em pacientes com pancreatite crônica. Conclusão - Não houve diferença estatisticamente significante no custo do tratamento de reposição enzimática entre pacientes pancreatectomizados com ou sem pancreatite crônica prévia à indicação cirúrgica.
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Idoso de 80 Anos ou mais , Pancreatectomia/efeitos adversos , Insuficiência Pancreática Exócrina/tratamento farmacológico , Neoplasias Pancreáticas/cirurgia , Pancreatite Crônica/cirurgia , Terapia de Reposição de Enzimas/economia , Insuficiência Pancreática Exócrina/economia , Insuficiência Pancreática Exócrina/etiologia , Estudos Transversais , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: Faecal elastase-1 (FE1) is a sensitive marker for exocrine pancreatic enzyme insufficiency. Pancreatic insufficiency (EPI) leads to maldigestion and subsequent poor weight gain. Thus, FE1 is performed as work-up for children with failure to thrive (FTT). However, EPI in the paediatric population outside of cystic fibrosis (CF) is rare. This study aimed to identify the indications for FE1 testing and their diagnostic yield in children. The secondary aim was to evaluate the cost per case of EPI detected for the various indications. DESIGN: All FE1 tests performed on children (0-18 years) at a tertiary paediatric hospital in Sydney, Australia between 2010 and 2013 (inclusive) were identified. A retrospective chart audit was performed to identify the indication for testing FE1. The diagnostic yield based on FE1 cut-offs <200 and < 100 µg/g were assessed. RESULTS: The most common indication for testing FE1 was "FTT only" (71/216, 32.9%), however, in this cohort of patients, FE1 was least likely to be positive with only 2 out of the 71 (2.8%) patients returning a positive result. In comparison, CF was the second most common indication for testing (60/216, 27.8%), but nearly half (48.8%) of tests returned a positive result in this cohort. The cost per case detected (FE1 <200 µg/g) reflected the test yield with an average cost per positive test of $262.50 (AUD2015) for FTT with short-gut syndrome and $420.00 (AUD2015) for CF-related indications. CONCLUSION: Our study shows that for patients with isolated failure to thrive, FE1 testing is low yield and costly.